Drug intelligence / Profile preview

HA131

Development stage: Phase 2
Lead developer: CSPC Pharmaceutical Group
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Hepatic Arterial Infusion

Overview

HA131 is a drug formulated as Paclitaxel Cationic Liposomes for injection. It exerts a dual anti-tumor action through the cytotoxic effect of paclitaxel and the targeting capabilities of cationic liposomes. The cationic liposomes target negatively charged tumor neovascular endothelial cells, blocking the supply of nutrients and inducing apoptosis of tumor cells. It is being investigated for the first-line treatment of gastrointestinal cancer with liver metastases.

Other names: Paclitaxel Cationic Liposomes for injection

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on HA131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HA131.

Explore the full profile